

Date: 30-05-2022

To, Cooperate Relation Department BSE LIMITED 1't Floor, Phiroze leejeebhoy Towers, Dalal Street, Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Half Year Ended on 31st March 2022.

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on 31st March 2022 published in FREE PRESS JOURNAL and NAVSHAKTI on 29th May, 2022 in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on 28th May, 2022.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,

For Colinz Laboratories Ltd.,

Dr. Mani L. S.

Director & Company Secretary

DIN: 00825886

CIN NO- L24200MH1986PLC041128

* FREE PRESS JOURNAL *

01-29/5/2022

THE FREE PRESS JOURNAL www

Noti mis issu shou else

NAN HOL VIJA DIEC

Note 1. Th

Regi

Plac

COLINZ LABORAT

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078: (CIN NO: L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 3151 MARCH, 2022"

		011	ADTED END	YEAR ENDED		
S. No.	PARTICULARS	QUARTER ENDED				
		Audited	Un-Audited		Audited 31-Mar-22 31-Mar-2	
		31-Mar-22	31-Dec-21	31-Mar-21		
1	Revenue from Operations	165.27	162.07	170.87	714.50	635.00
2	Net Profit/(Loss) for the period(before Tax, Exceptional and/or Extraordinary Items).	12.40	10.81	5.94	48.03	24.52
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	12.40	10.81	5.94	48.03	24.52
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	7.01	8.56	5.93	33.93	20.76
5	Total Comprehensive Income for the period(Comprising Profit/(Loss) for the period(after tax) and Other Comprehensive Income(Net of Tax).	3.80	6.95	4.38	39.61	45.22
6	Equity Share Capital (Face Value of Rs. 10/- each).	354.50	354.50	354.50	354.50	354.50
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)	l V e	oralda Laukka		7 lana (43 Hadasara)	an indirec
	1) Basic	0.15	0.19	0.13	0.74	0.45
	2) Diluted	0.15	0.19	0.13	0.74	0.45

1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th May ,2022.

2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.

3) The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.

4) Previous period figures have been regrouped/rearranged/reclassified, wherever necessary.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128 Dr. MANI L. S.

(Director & Company Secretary) (DIN NO: 00825886)

MUMBAI. 28th May, 2022.



*NAV SHAKTI * D+-29/05/2022

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO: L24200MH1986PLC041128)

" EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31st March, 2022'

				(Rs. In "Lacs")		
	PARTICULARS	QUARTER ENDED			YEAR ENDED	
S.		Audited	Un-Audited	Audited	Audited	
No.		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
1	Revenue from Operations	165.27	162.07	170.87	714.50	635.00
2	Net Profit/(Loss) for the period(before Tax, Exceptional and/or Extraordinary Items).	12.40	10.81	5.94	48.03	24.52
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	12.40	10.81	5.94	48.03	24.52
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	7.01	8.56	5.93	33.93	20.76
5	Total Comprehensive Income for the period(Comprising Profit/(Loss) for the period(after tax) and Other Comprehensive Income(Net of Tax).	3.80	6.95	4.38	39.61	45.22
6	Equity Share Capital(Face Value of Rs. 10/- each).	354.50	354.50	354.50	354.50	354.50
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.) 1) Basic	0.15 0.15	0.19	0.13 0.13	0.74 0.74	0.45 0.45
	2) Diluted	0.10	0.19	0.10		0.

NOTES :-

1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th May ,2022.

2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.

3) The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.

4) Previous period figures have been regrouped/rearranged/reclassified, wherever necessary.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128 Dr. MANI L. S.

MUMBAL 28th May, 2022. (Director & Company Secretary) (DIN NO: 00825886)

